Homologous Recombination Deficiency clinical trials at UC Health

• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

  open to eligible people ages 18 years and up

  ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (dose escalation) is to confirm the appropriate treatment dose. The purpose of Phase II (dose expansion) is to characterize the safety and efficacy of AMXI-5001.

  at UCLA

Last updated: August 13, 2020